BSETrident Texofab LtdMediumNeutral
Announced Sat, 14 Feb · 14:43 IST

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Earnings Presentation for the quarter and Nine months ....

Mgmt Guided Margin ImprovementInvestor Communications View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Trident Texofab Ltd filed its Q3 FY26 (quarter ended Dec 31, 2025) earnings presentation with BSE. Revenue from Operations fell 19% YoY to Rs 2,574.09 lakhs, while EBITDA declined 29% YoY to Rs 164.50 lakhs with EBITDA margins compressing by 94 basis points to 6.39%. Despite the top-line weakness, Profit After Tax grew 90% YoY to Rs 57.01 lakhs on a lower base, supported by a 37% drop in interest costs. For 9M FY26, PAT rose 65% YoY to Rs 361.65 lakhs. The shareholder's fund nearly tripled to Rs 4,723.87 lakhs in FY25 following a recent capital infusion. Manufacturing contributed 61.8% of Q3 FY26 revenue (vs 63.3% YoY), with management reiterating its focus on scaling manufacturing to improve blended profitability.

Likely market impact

Mixed signals for shareholders - topline decline and margin compression in Q3 raise concerns about demand, while PAT growth driven by lower interest costs and a recent capital infusion is positive. Continued shift toward higher-margin manufacturing remains the key medium-term thesis.